Geron Corporation operates as a biopharmaceutical company. The company supports the clinical stage development of imetelstat, a telomerase inhibitor for the treatment of hematologic myeloid malignancies. It has collaboration and license agreement with Janssen Biotech, Inc. to develop and commercialize imetelstat worldwide for indications in oncology, including hematologic myeloid malignancies and other human therapeutic uses. The company was founded in 1990 and is based in Menlo Park, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Phone650-473-7700
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$1.07 million
Profitability
Miscellaneous
Employees18
OptionableOptionable
Geron (NASDAQ:GERN) Frequently Asked Questions
What is Geron's stock symbol?
Geron trades on the NASDAQ under the ticker symbol "GERN."
How were Geron's earnings last quarter?
Geron Co. (NASDAQ:GERN) posted its quarterly earnings data on Thursday, November, 1st. The biopharmaceutical company reported ($0.03) earnings per share for the quarter, beating analysts' consensus estimates of ($0.05) by $0.02. The biopharmaceutical company earned $0.17 million during the quarter, compared to analyst estimates of $0.22 million. Geron had a negative net margin of 3,077.78% and a negative return on equity of 19.16%. View Geron's Earnings History.
When is Geron's next earnings date?
What price target have analysts set for GERN?
5 equities research analysts have issued 1-year target prices for Geron's stock. Their forecasts range from $1.80 to $7.00. On average, they expect Geron's stock price to reach $4.01 in the next twelve months. This suggests a possible upside of 170.9% from the stock's current price. View Analyst Price Targets for Geron.
What is the consensus analysts' recommendation for Geron?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Geron in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Geron.
Has Geron been receiving favorable news coverage?
News articles about GERN stock have trended somewhat negative this week, according to InfoTrie Sentiment Analysis. The research firm scores the sentiment of press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Geron earned a news impact score of -1.1 on InfoTrie's scale. They also assigned news articles about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the company's share price in the near term.
Are investors shorting Geron?
Geron saw a increase in short interest in January. As of January 31st, there was short interest totalling 35,227,714 shares, an increase of 2.3% from the January 15th total of 36,046,089 shares. Based on an average daily volume of 2,101,947 shares, the short-interest ratio is currently 16.8 days. Approximately 19.0% of the shares of the company are sold short. View Geron's Current Options Chain.
Who are some of Geron's key competitors?
Some companies that are related to Geron include Amphastar Pharmaceuticals (AMPH), Wave Life Sciences (WVE), Vanda Pharmaceuticals (VNDA), Deciphera Pharmaceuticals (DCPH), Rhythm Pharmaceuticals (RYTM), Puma Biotechnology (PBYI), Epizyme (EPZM), Alder Biopharmaceuticals (ALDR), Tricida (TCDA), Kiniksa Pharmaceuticals (KNSA), MacroGenics (MGNX), CannTrust (CNTTF), Homology Medicines (FIXX), Advanz Pharma (CXRXF) and Retrophin (RTRX).
Who are Geron's key executives?
Geron's management team includes the folowing people:
- Dr. John A. Scarlett, CEO, Pres & Chairman (Age 68)
- Ms. Olivia Kyusuk Bloom, Exec. VP of Fin., CFO & Treasurer (Age 50)
- Dr. Andrew J. Grethlein, Exec. VP & COO (Age 55)
- Mr. Stephen N. Rosenfield, Exec. VP & Chief Legal Officer (Age 69)
- Ms. Melissa A. Kelly Behrs, Exec. VP & Chief Bus. Officer (Age 55)
Who are Geron's major shareholders?
Geron's stock is owned by a number of of retail and institutional investors. Top institutional investors include BlackRock Inc. (8.07%), Northern Trust Corp (1.16%), Geode Capital Management LLC (1.02%), Two Sigma Investments LP (0.53%), Millennium Management LLC (0.40%) and Bank of New York Mellon Corp (0.38%). Company insiders that own Geron stock include Robert J Spiegel and Stephen Rosenfield. View Institutional Ownership Trends for Geron.
Which major investors are selling Geron stock?
GERN stock was sold by a variety of institutional investors in the last quarter, including Barclays PLC, New York State Common Retirement Fund, Bank of New York Mellon Corp, Jane Street Group LLC and Raymond James Financial Services Advisors Inc.. Company insiders that have sold Geron company stock in the last year include Robert J Spiegel and Stephen Rosenfield. View Insider Buying and Selling for Geron.
Which major investors are buying Geron stock?
GERN stock was bought by a variety of institutional investors in the last quarter, including Millennium Management LLC, BlackRock Inc., Two Sigma Investments LP, D. E. Shaw & Co. Inc., Ibex Investors LLC, Virtu Financial LLC, Northern Trust Corp and Virtus ETF Advisers LLC. View Insider Buying and Selling for Geron.
How do I buy shares of Geron?
Shares of GERN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Geron's stock price today?
One share of GERN stock can currently be purchased for approximately $1.48.
How big of a company is Geron?
Geron has a market capitalization of $275.80 million and generates $1.07 million in revenue each year. The biopharmaceutical company earns $-27,910,000.00 in net income (profit) each year or ($0.18) on an earnings per share basis. Geron employs 18 workers across the globe.
What is Geron's official website?
How can I contact Geron?
Geron's mailing address is 149 COMMONWEALTH DRIVE SUITE 2070, MENLO PARK CA, 94025. The biopharmaceutical company can be reached via phone at 650-473-7700 or via email at [email protected]
MarketBeat Community Rating for Geron (NASDAQ GERN)
MarketBeat's community ratings are surveys of what our community members think about Geron and other stocks. Vote "Outperform" if you believe GERN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GERN will underperform the S&P 500 over the long term. You may vote once every thirty days.
